The Management of Cardiometabolic Risk in MAFLD: Therapeutic Strategies to Modulate Deranged Metabolism and Cholesterol Levels
Medicina,
Journal Year:
2025,
Volume and Issue:
61(3), P. 387 - 387
Published: Feb. 23, 2025
Background
and
Objectives:
Fatty
Liver
Disease
is
a
major
health
problem
worldwide.
We
can
distinguish
liver
steatosis
as
non-associated
or
associated
with
chronic/acute
alcohol
consumption.
These
two
entities
share
similar
stages
ranging
from
hepatic
fat
storage
(namely,
steatosis)
to
inflammation,
necrosis,
fibrosis
until
hepatocellular
carcinoma
(HCC).
Over
time,
“Metabolic
Associated
Disease”
(MAFLD)
has
replaced
nonalcoholic
fatty
disease
(NAFLD)
nomenclature
included
cardiometabolic
criteria
in
these
patients
definition.
Thus,
obesity,
type
2
diabetes
mellitus
(T2DM),
hypertension,
dyslipidemia
are
MAFLD
features
of
the
metabolic
syndrome.
Importantly,
there
not
specific
treatment
for
MAFLD,
but
therapeutic
strategies
that
act
on
dysfunction
related
MAFLD.
They
reduce
progression
its
complications.
Materials
Methods:
For
all
reasons,
we
conducted
narrative
review
literature,
focused
special
regard
cholesterol
metabolism.
Results:
recently
redefined
condition
better
describes
metabolism
derangement
responsible
disease.
This
distinguishes
NAFLD.
In
fact,
diagnostic
require
presence
together
at
least
one
following:
T2DM,
evidence
disorder
such
hypertriglyceridemia,
low
high-density
lipoprotein
cholesterol,
hypertension.
As
result,
closely
linked
an
increased
risk.
Current
approaches
be
used
this
risk,
focusing
lifestyle
interventions
pharmacological
strategies.
Several
treatments
diagnosed
mainly
cholesterol-lowering
remedies.
Among
these,
Pro-protein
Convertase
Subtilisin/Kexin
9
inhibitors
(PCSK9i)
show
most
promising
efficacy
profile
data
lacking.
Agonists
GLP-1
receptor,
Sodium-glucose
cotransporter-2
(SGLT2i)
Dipeptidyl
Peptidase-4
(DPP-4i)
have
“
multi-hit
action
allowing
their
use
also
diabetic
Conclusions:
Lifestyle
modifications,
some
nutraceuticals,
statins,
incretins,
PCSK9i
changed
natural
course
significantly
improved
outcomes
Emerging
drugs,
Bempedoic
acid,
overcome
compliance
statins’
controversial
effect
fibrosis.
Finally,
medications
targeting
insulin
resistance
allow
strategic
convoluted
pathophysiology
multiple
steps,
potential
steatosis,
necrosis
and,
sometimes
even
reverse
Language: Английский
The Role of Platelet Dysfunctions in the Pathogenesis of the Hemostatic-Coagulant System Imbalances
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(6), P. 2756 - 2756
Published: March 19, 2025
Platelet
dysfunction
plays
a
critical
role
in
the
pathogenesis
of
various
disorders
affecting
hemostatic-coagulant
system.
This
review
aims
to
explore
mechanisms
by
which
platelet
dysfunctions
contribute
disruption
hemostasis,
leading
an
increased
risk
both
thrombosis
and
bleeding.
Platelets,
traditionally
known
for
their
clot
formation,
can
exhibit
altered
functionality
under
pathological
conditions
such
as
cardiovascular
diseases,
metabolic
disorders,
autoimmune
impacting
interaction
with
coagulation
factors
vascular
endothelium.
The
discusses
molecular
cellular
underlying
dysfunction,
including
aberrations
activation,
aggregation,
secretion.
It
also
highlights
interplay
between
platelets
other
components
cascade,
fibrinogen
clotting
factors,
maintaining
integrity.
Moreover,
examines
clinical
implications,
how
be
contributing
factor
like
deep
vein
thrombosis,
stroke,
disseminated
intravascular
(DIC).
Finally,
current
therapeutic
approaches
targeting
dysfunctions,
antiplatelet
agents
emerging
therapies,
are
reviewed
provide
insights
into
potential
strategies
managing
fluid-coagulation
system
imbalances.
underscores
importance
comprehensive
understanding
improve
diagnosis
treatment
hemostatic
disorders.
Language: Английский